Press Releases BioLineRx Ltd. Nasdaq

Equities

BLRX

US09071M2052

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
0.6419 ^USD	+4.04%		-2.71%	-59.11%

17/04	BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	CI
10/04	BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	06/05	PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04	PU
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04	PR
BioLineRx Announces $6 Million Registered Direct Offering	02/04	AQ
BioLineRx : Form 20-F/A (Amendment No. 1	28/03	PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	27/03	AQ
BioLineRx : Annual Report on Form 20-F FOR 2023	26/03	PU
BioLineRx : Report of Periodic or Interim Report	26/03	PU
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	26/03	PU
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	20/03	PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	04/03	PR
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	31/12	PU
BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan	31/12	PU
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	21/12	PR
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	21/11	AQ
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023	13/11	PR
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures	31/23/31	PR
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer	29/23/29	AQ
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer	20/23/20	AQ
BioLineRx Announces FDA Approval of APHEXDA in Combination with Filgrastim to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma	12/23/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioLineRx Ltd. Nasdaq

Equities

BLRX

US09071M2052

Press Releases

Filters